Navigation Links
VTT and GE Healthcare developing novel biomarkers to predict Alzheimer's disease

Scientists from VTT Technical Research Centre of Finland in collaboration with the University of Eastern Finland have recently discovered a serum biochemical signature which predicts progression to Alzheimer's disease months or even years before the first symptoms of the disease occur. The goal of the new collaboration between VTT and GE Healthcare is to validate this biomarker in a large patient cohort as well as to discover novel biomarker candidates.

Alzheimer's disease (AD) is a growing challenge to the health care systems and economies of developed countries with millions of patients suffering from this disease and increasing numbers of new cases diagnosed annually with the increasing ageing of populations.

Early detection of prodromal AD is vital both for assessing the efficacy of potential AD therapeutic agents as well as new disease modifying therapies are most likely to be effective when initiated during the early stages of disease. The elucidation of early metabolic pathways associated with progression to Alzheimer's disease may also help in identifying new therapeutic avenues.

In 2010 GE Healthcare entered into "biosignatures initiative" alliance with Janssen Pharmaceutica N.V. (Janssen) to develop diagnostic biosignatures for pre-symptomatic identification of AD. As part of this programme, VTT will apply serum metabolite profiling to validate their recently discovered biochemical signature, as well as to discover novel biomarker candidates predictive of progression to AD.

VTT's research professor Matej Oreič said: "We are excited about the prospect of collaborating with GE Healthcare to accelerate its research programs and to further develop our biomarker towards a clinical assay applicable in healthcare setting. VTT has over the past years built unique metabolomics and systems biology platforms and acquired vast amount of knowledge on metabolic profiles and pathways in human health and disease, which allow us to identify disease-specific biochemical signatures and pathways. We believe that integration of metabolomics into the GE's and Janssen's biosignatures initiative will lead to better tools for early detection of AD and may also lead to better therapeutic options."


Contact: Sampo Sammalisto
VTT Technical Research Centre of Finland

Related biology news :

1. BGI, GE Healthcare team up on pioneering stem cell science projects
2. Premier Healthcare Renews Supplier Agreement with Masimo
3. Early Bird Offers on Healthcare and Biotechnology Conferences, Save Up To 20% by Registering with Global Information
4. Bioethics for Beginners: 60 Cases and Cautions from the Moral Frontier of Healthcare
5. Boston Healthcare Associates Roundtable Explores Challenges and Opportunities Surrounding the Value of Big Data within the Life Sciences
6. Early Bird Discounts Available on International Healthcare and Biotechnology Conferences, Save Up To $600 with Global Information
7. Attendees Save Up To $800 on Boston-area Pharmaceutical and Healthcare Conferences, Early Bird Discounts Expiring April 27
8. Agricultural expert outlines path for developing nations to double food production, meet 2050 demand
9. Medbox Developing a Patent Pending Wall-Mounted Biometric Kiosk for Storage of Sensitive Medicine Samples and Supplies for Doctors Offices.
10. Research4Life greatly expands peer-reviewed research available to developing world
11. Family history of liver cancer increases risk of developing the disease
Post Your Comments:
(Date:10/8/2015)... , October 8, 2015 ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet announces that revenues for ... approximately $410,000 compared with $113,00 for the three ... 9 months ended September 30, 2015 were approximately ...
(Date:10/5/2015)... , October 5, 2015 ... company update for NXT-ID, Inc. (NASDAQ: NXTD ), ... commerce market. --> ) ... Inc. (NASDAQ: NXTD ), a biometric authentication company ... SoundView Technology Group ( ) ...
(Date:9/30/2015)... Sept. 30, 2015  The global glucose monitoring device and ... So says a new report on the industry from Kalorama ... dominate the market, followed by continuous glucose monitoring and sensor ... the market for these products in its latest report, ... , ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... JACKSONVILLE, Florida , October 13, 2015 ... company specializing in the development of innovative peptide and ... & metastatic disease, will be a featured presenting company ... at the Wyndham Grand Hotel in ... --> TapImmune, Inc. (TPIV), a clinical-stage immunotherapy ...
(Date:10/13/2015)... , Oct. 13, 2015  Generex Biotechnology Corporation ( ... into a non-binding Letter of Intent (LOI) with MediTemp Ltd. ... developed a proprietary cooling technology designed to improve sperm quality ... the United States and three million men in ... and 44 diagnosed as infertile.  For 42% of those men, ...
(Date:10/13/2015)... ... 13, 2015 , ... Clinovo recently appointed Jeff Parr and Ed Donaldson to ... data solutions business. , Jeff Parr has spent the past decade providing quality management ... Thermo Fisher, and Ab Sciex to name a few. He is based in ...
(Date:10/13/2015)... ... October 13, 2015 , ... Proove ... to announce their partnership with the Keck Medicine of the University of ... , The T.R.O.J.A.N. Study (Therapeutic Evaluation to Research Clinical Objectives Linking Genotypic and ...
Breaking Biology Technology: